The level of FGD3 strongly impacted whether cancer cells that undergo cell swelling and ATP depletion induced by several agents, FDA-approved aprepitant/EmendTM (necrosis inducer), shikonin (necroptosis inducer) and doxorubicin (pyroptosis inducer) proceed to PMR and cell death. This evidence concerns the gene FGD3 and cancer.